Biogen Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?

Biogen Inc. vs. CRISPR Therapeutics AG: A Decade of SG&A Management

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Biogen Inc. and CRISPR Therapeutics AG have demonstrated contrasting approaches to SG&A cost management.

Biogen Inc., a stalwart in the industry, has consistently maintained high SG&A expenses, averaging around $2.28 billion annually. Despite fluctuations, Biogen's expenses peaked in 2021, reflecting a strategic investment in administrative capabilities. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, has shown a more conservative approach, with SG&A expenses averaging approximately $57 million annually. This represents just 2.5% of Biogen's average, highlighting CRISPR's lean operational model.

From 2014 to 2023, Biogen's SG&A expenses grew by about 14%, while CRISPR's surged by over 1,900%, indicating rapid expansion. This data underscores the diverse strategies these companies employ in navigating the biotech sector's financial challenges.